Adaptimmune and GSK Expand Strategic Immunotherapy Collaboration Adaptimmune Therapeutics plc and GlaxoSmithKline plc (GSK) announced that the companies have expanded the terms of their strategic collaboration agreement to accelerate Adaptimmune’s lead clinical cancer program, an affinity enhanced T-cell immunotherapy (GSK3377794) targeting NY-ESO-1, toward pivotal trials in synovial sarcoma. [Adaptimmune Therapeutics plc] Press Release Dana-Farber Cancer Institute’s Belfer Center Announces Immuno-Oncology Research Collaboration with Array BioPharma Dana-Farber Cancer Institute announced an immuno-oncology collaboration with potential applicability in a wide range of oncology indications with Array BioPharma. The research team at Dana-Farber will work with Array scientists on novel immune-oncology targets with the goal of bringing innovative medicines to patients. [Dana-Farber Cancer Institute] Press Release Dream Team Gets $11.7 Million to Fight Brain Cancers A “Dream Team” of top Canadian scientists, led by two outstanding figures in stem cell research, is launching a new attack on brain cancers. The team will receive $11.7 million over four years from Stand Up To Cancer Canada, Genome Canada, the Canadian Institutes of Health Research, the Cancer Stem Cell Consortium, and Ontario Institute for Cancer Research. [Canadian Stem Cell Foundation] Press Release NUI Galway Launch €6 Million Robotic Stem Cell Production Project NUI Galway’s Regenerative Medicine Institute has launched a new €6 million research project AUTOSTEM to develop pioneering manufacturing systems for stem cell therapy. Funded by the EU Horizon 2020 program, AUTOSTEM will go a long way towards meeting the demand for these new treatments, by transforming the way stem cells are manufactured. [National University of Ireland, Galway] Press Release With $3 Million Award, HSU Generates Stem Cell Scholars Humboldt State University (HSU) biology professors Jacob Varkey and Amy Sprowles are among educators at 12 universities to secure funding from the California Institute for Regenerative Medicine’s Bridges 2.0 Training Program. The award of $3,044,950 will fund stem cell training for HSU students and support up to ten paid research internships annually for the next five years. [Humboldt State University] Press Release NIH Awards $2.8 Million to FAU Researchers and Collaborators The National Eye Institute of the National Institutes of Health (NIH) has awarded a $2.8 million, multi-institution grant to define the mechanisms that govern how cells decide whether to become a mature cell or whether to die. [Florida Atlantic University] Press Release Terry Fox Award Helps Ottawa Researcher Develop Next-Generation Cancer Immunovirotherapy The Terry Fox Research Institute has awarded Dr. Guy Ungerechts (The Ottawa Hospital and the University of Ottawa) a $450,000 New Investigator grant to develop innovative new treatments to destroy cancer cells and stimulate a patient’s own immune system to attack tumors, while leaving healthy tissues unharmed. [Terry Fox Research Institute] Press Release Regenerative Medicine Awards Lay Groundwork for Therapies of Tomorrow Two collaborative teams within USC Stem Cell are developing new approaches that could eventually help patients with heart disease, frontotemporal dementia and amyotrophic lateral sclerosis. Totaling $140,000 each, the awards support USC-affiliated faculty members pursuing multi-investigator research collaborations with the goal of curing diseases using stem cells as tools. [University of Southern California] Press Release New Department of Defense Grant Funds Efforts to Treat ALS with Stem Cells Evan Snyder, M.D., Ph.D. was awarded a grant to develop a stem cell treatment for amyotrophic lateral sclerosis (ALS). This grant will support research on human neural stem cells as an approach to support the survival and function of existing motor neurons. [Sanford Burnham Prebys Medical Discovery Institute] Press Release OSE Pharma Announces U.S. Initiation of Atalante 1, the Company’s Global, Pivotal Phase III Trial for Tedopi® Immunotherapy in Non-Small Cell Lung Cancer OSE Pharma SA announced initiation in the United States of its Phase III clinical trial, Atalante 1. This global, pivotal trial will evaluate Tedopi®, the company’s lead product, for advanced non-small cell lung cancer. [OSE Pharma SA] Press Release |